Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


Ethan Guillen UAEM AAAS Presentation July 26, 2010

General discussion of UAEM and our work

Ethan Guillen

on 12 August 2010

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Ethan Guillen UAEM AAAS Presentation July 26, 2010

Global Access Licensing The Role of the University? Who we are About UAEM Vision & Mission History 2001 d4T costs $1,600/patient/year - Doctors Without Borders (MSF) seeks Yale’s permission to use generic d4t in South Africa

Yale balks, claiming its “hands are tied” by licensee
Students at Yale organize

March 24, 2001: Yale asks BMS to grant “patent relief” and price cuts

Generic competition drops the price of d4t in South Africa 96% within a year - to $55, allowing Doctors Without Borders to scale-up HIV treatment programs across Africa

Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent strategy to make affordable versions available in resource-limited countries for essential medical care. Though licenses are complex, and each will be unique, aspire to the following goals:


1. Access to medicines is the primary purpose of technology transfer

2. Technology transfer should preserve future innovation by ensuring that intellectual property does not act as a barrier to further research.


3. Generic competition is the most efficient method of facilitating affordable access. In the cases of biologic compounds or other drugs where generic provision is forecast to be technically or economically infeasible, “at-cost” or other provisioning requirements should be used as a supplement to generic provisioning terms.

4. Proactive licensing provisions are essential to ensure that follow-on patents and data exclusivity cannot be used to block generic production.

5. University technology transfer programs should facilitate future innovation by patenting only when truly necessary to promote commercialization, utilizing non-exclusive licensing, streamlined processes for materials transfer, and reserving rights to use technology in future research.

6 .A global access licensing policy should be systematic, sufficiently transparent to verify effectiveness, and based on metrics that measure the success by its impact on access and continued innovation. Students of law, medicine, public health, business, undergrad and many others at over 60 chapters globally. Our Vision

Universities and publicly funded research institutions will be part of the solution to the access to medicines crisis by promoting medical innovation in the public interest and ensuring that all people regardless of income have access to essential medicines and other health-related technologies. Our Mission

As a private non-profit organization rooted in a movement of university students, UAEM aims to

- promote access to medicines for people in developing countries by changing norms and practices around university patenting and licensing

- ensure that university medical research meets the needs of the majority of the world’s population

- empower students to respond to the access and innovation crisis Our Values

As committed students from all over the world who passionately believe in social justice and health equity, we find it unacceptable that millions of people do not have access to essential medicines. We are particularly concerned about people in developing countries who are disproportionately affected by the access to medicines crisis.

Universities have a social compact with society and, as educational and research institutions, they have a responsibility to promote and manage the deployment of innovations for the public benefit. In no field are the moral imperatives to do so as clear as they are in medicine.

Students are uniquely positioned to push for normative change in their universities and research institutions. We will use the intellectual sophistication, rigour and integrity of our members to fight for increased innovation as well as access to medicines and health-related technologies for all.

Our work is guided at all times by principles of non-partisanship, democracy, transparency and respect. Why Universities Matter UC Medicines Hep B

Vaccine discovered, patented by UCSF (1979, 1981)
2 billion infected worldwide, 65 million new infections each year
In the 87 countries with ≥8% chronic HBV infection prevalence, HepB vaccine birth dose coverage was 36%.
National immunization programs could cut deaths by over 80%.

UCSF and Duke synthesize and are awarded a patent for a novel viral fusion inhibitor, Fuzeon (enfuvirtide), a last-line HIV drug.

Fuzeon licensed to Roche, which:
Placed on the market for $22,000/pt/yr making it the most expensive HIV drug ever.
Has not bothered to register Fuzeon in many low-and middle income countries
Has no plans to reduce drug’s cost for developing country patients (6/08) Universities key to innovation More than 1/3 of HIV drugs introduced between 2001 and 2006 involve a university patent.
Not a single vaccine has been brought to market in the past 25 years that has not had a contribution from university research.
In 2000, a U.S. Senate report noted that of the 21 drugs with the greatest therapeutic impact as determined by a panel of experts, 15 were developed using research funded by the United States government.
86 Nobel winners in medicine in previous 30 years: 80 from academia, 6 from industry. Association of University Technology Managers Association of American Universities 2008

AUTM representative part of industry lobbying delegation at WHO

AUTM encourages members to fight innovative R&D recommendations

UAEM action gains AUTM apology 2010

HHS panel recommends changes to patenting and licensing of genes to improve access and innovation (would avoid BRCA gene test problem)

AUTM joins industry in fighting recommendations

UAEM is campaigning to get AUTM to retract 2009

AAU joins industry fight for excessive monopolies on generic biologics

UAEM and AMSA lobby in opposition

Excessive monopolies - and entrenched high prices - are passed as part of healthcare reform ethan.guillen@essentialmedicine.org Paulo Barcellos Jr. used under the Creative Commons Attribution ShareAlike 2.0 license. UC Mission statement: "The distinctive mission of the University is to serve society as a center of higher learning, providing long-term societal benefits through transmitting advanced knowledge, discovering new knowledge, and functioning as an active working repository of organized knowledge.” Nobel Laureates

Peter Agre—2003 Nobel Laureate in Chemistry, Vice Chancellor for Science and Technology, James B. Duke Professor of Cell Biology, Duke University Medical Center
Kenneth Arrow—1972 Nobel Laureate in Economics; 2004 National Medal of Science; Professor of Economics (Emeritus), Stanford University
Craig Mello—2006 Nobel Laureate in Medicine; Professor of Molecular Biology, University of Massachusetts Medical School
John Polanyi—1986 Nobel Laureate in Chemistry; Professor, University of Toronto
Oliver Smithies—2007 Nobel Laureate in Medicine, Excellence Professor, UNC-Chapel Hill
Jack Steinberger—1988 Nobel Laureate in Physics
Sir John Sulston—2002 Nobel Laureate in Medicine
Desmond Tutu—1984 Nobel Peace Prize winner, human rights activist
Harold Varmus—1989 Nobel Laureate in Medicine; Founder of Public Library of Science (PLoS); Chairman of the Scientific Board of Grand Challenges in Global Health Science and medicine

OrganizationsAmerican Medical Students AssociationDignitas InternationalInstitute for OneWorld HealthInternational Federation of Medical Students Associations (IFMSA)Medecins Sans Frontieres (MSF)'s Campaign for Access to Essential MedicinesMedsin-UKOxfam InternationalPartners in Health

Dr. Robert Einterz—Indiana University Associate Dean of the IU-Kenya Partnership
David A. Hamburg, MD—President Emeritus, Carnegie Corporation of NY; DeWitt Wallace Distinguished Scholar; Co-Chair, Social Medicine and Public Policy Programs, Department of Psychiatry, Weill Cornell Medical College
Robert E. Johnston, PhD—Professor of Microbiology and Immunology, Director of the Carolina Vaccine Institute, Director of Global Vaccines Inc., UNC-Chapel Hill
Samuel Katz, MD—2007 Pollin Prize recipient, Wilburt C. Davison Professor & Chairman Emeritus of pediatrics, Duke University
Mario Stevenson, PhD—Director of Center for AIDS Research and Professor of Molecular Biology, University of Massachusetts Medical School
John Sullivan, MD—Director of Office of Research, University of Massachusetts Medical School
Public health and policy

Dr. Chris Byrer—Professor, Johns Hopkins School of Public Health; Director, Johns Hopkins Fogarty AIDS International Training and Research Program; Director, Johns Hopkins Center for Public Health & Human Rights; Senior Scientific Liaison, HIV Vaccine Trials Network; Associate Director, Center for Global Health
Paul Farmer—Presley Professor of Medical Anthropology, Harvard University
Sir Richard Feachem—Professor of International Health at the University of California San Francisco and Berkeley, former Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria
Donald A. Henderson, MD, MPH—Dean Emeritus, Johns Hopkins School of Public Health; Professor Emeritus, Johns Hopkins School of Public Health; former Director of the World Health Organization’s Global Smallpox Eradication Campaign
Jim Yong Kim—François-Xavier Bagnoud Professor of Health and Human Rights, Harvard University
James Orbinski—Associate Professor Medicine and Politcal Science & Munk Centre for International Studies, University of Toronto; former International President of Médecins Sans Frontières
Dr. Thomas Quinn—Professor; Director of the Johns Hopkins Center for Global Health
Jeffrey Sachs—Director, Earth Institute at Columbia University and Director, UN Millennium Project
Civil society

Zackie Achmat—Founder and Chairman, Treatment Action Campaign
Victoria Hale—Founder and former CEO of the Institute for OneWorld Health
Stephen Lewis—Former UN Special Envoy for HIV/AIDS in Africa
Bernard Pecoul—Executive Director of the Drugs for Neglected Diseases Initiative Statement of Principles and Strategies:

Commitments to:
•limit patenting in developing countries
•in cases where there are patents, license in such a way that patents barriers are minimized
•acknowledgement of fully enabling generic production as a strategy
•investing in research and development on diseases that impact poor countries
•developing public metrics that measure the global health impact of university policies
•revisiting and revising the principles document biennially

•unclear whether the Statement of Principles will ensure access to medicines for the poor in India, China, and Brazil
•ambiguity also leaves unclear the ability of generic manufacturers in these critical countries to produce medicines for countries without manufacturing capacity
•does not adequately emphasize the important role that generic competition plays in reducing the price of drugs, and thus enhancing access University of British Columbia
University of Washington
Emory University
University of Edinburgh
Boston University
UC Berkeley
University of North Carolina
Association of University Technology Managers
Boston University
Brown University
Harvard University
University of Pennsylvania
Yale University
Oregon Health & Science University
National Institutes of Health
University of Illinois Chicago
University of Illinois Urbana-Champaign
Centers for Disease Control and Prevention
University of Vermont and State Agricultural College
Duke University and Duke Medicine
University of British Columbia
Bilkent University
El Colegio de México
New York University
Tecnologico de Monterrey
Jawaharlal Nehru University
Najit Technologies, Inc.
Brigham & Women's Hospital
Florida State University
Massachusetts General Hospital www.academicsforaccess.org Wrap Up

1. Universities matter to drug discovery
2. Though there are clearly great benefits from university research, universities can be bad actors - the voice of academics is important
3. Global Access Licensing is achievable in the short-term and can have considerable impact
Full transcript